q&a: gardp and venatorx collaboration to develop new treatment for multidrug-resistant infections
Published 4 years ago • 537 plays • Length 42:20Download video MP4
Download video MP3
Similar videos
-
1:31:38
bringing new treatments for drug resistant infections to all who need them
-
12:41
post-approval economics for new antibiotics: supply chain robustness, inventory build, and qa
-
41:29
post-approval economics for new antibiotics: q&a
-
43:50
antimicrobial resistance in drug discovery: q&a
-
1:16
difficult-to-treat resistance (dtr)
-
1:22:57
openly accessible resources for the global antimicrobial r&d community
-
1:30:55
combination antibiotic therapy against drug-resistant bacteria: where the evidence stands
-
1:02:22
webinar 7 july 2022 - breaking down access barriers for antibiotics: cefiderocol as a pathfinder
-
1:14:40
clinical trial platforms for new and neglected antimicrobials
-
4:50
post-approval economics for new antibiotics: additional economic considerations
-
1:29:23
efflux inhibitors: a strategy to tackle multidrug resistance
-
57:05
5by25 - live webinar / q&a with manica balasegaram
-
1:27:20
models for antimicrobial r&d: advanced and complex in vivo models for infectious disease research
-
2:23
endpoints for antibacterial trials: microbiologic
-
4:51
an overview of multidrug-resistant bacterial infections
-
1:07:07
new approaches to antibiotic discovery
-
0:24
grip - how important are policy decisions in the battle against antibiotic resistance?
-
57:52
what does the future look like if pull incentives to support antibiotic r&d are insufficient?
-
0:38
gvs acquires 100% of the rpb safety group